AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

AbbVie (NYSE:ABBV) recently showcased significant advances in oncology, particularly with the introduction of new pipeline ...

AbbVie (NYSE:ABBV) has recently seen promising developments with the release of favorable final results from the MIRASOL ...

AbbVie (ABBV) closed the most recent trading day at $213.85, moving -0.29% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.07%. At the same time, ...

AbbVie recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative colitis, building on Health Canada's prior approval. This significant development may ...

If you're interested in broad exposure to the Large Cap Value segment of the US equity market, look no further than the SPDR Portfolio S&P 500 High Dividend ETF (SPYD), a passively managed exchange ...

These four companies have raised their dividends over an impressive streak of 25 years or more. The post 4 US Dividend ...

Enigma Biomedical USA, Inc. (EB USA) today announced that it has selected two (2) four-repeat tau (4R Tau) protein PET imaging biomarkers to advance into Phase 1 (Ph1) studies. Previously, EB USA ...

AbbVie Inc. (NYSE:ABBV ... Fox Business, Barron’s, and Yahoo! Finance… But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could ...

The number of hedge funds tracked by Insider Monkey owning stakes in AbbVie Inc. (NYSE:ABBV) grew to 84 in Q4 2024, from 68 ...

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma (ZLDPF), the companies announced Wednesday. The deal would give ...